Technology relates to a novel liposome formulation for delivery of anticancer agents such as Docetaxel (DTX) with significantly higher antitumor efficacy, preparation is simple and easy to scale up. The present formulation significantly improves the biopharmaceutics of difficult-to-deliver drugs such as DTX. About 10-15-fold and 20-25 fold increase in the circulation half-life and mean residence time was observed upon incorporation of DTX in TPGS-Liposomes, as compared to Taxotere.
For more details about technology: Click here